The hope is that the two drugs could be combined with new KRAS inhibitor drugs from Amgen and Mirati to ... coming after two alliances in the protein degradation category with Amphista and Evotec.

Amgen (Thousand ... targeting four G–protein–coupled receptors, including Epix's PRX–03140, a small–molecule 5–hydroxytryptamine 4 receptor agonist for the treatment of Alzheimer's ...

Results Survey results for the definition of remission suggested indexes at published thresholds and a count of core set measures, with each measure scored as 1 or less (eg, tender and swollen joint ...

One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

have made a discovery that could change the treatment of colorectal cancer (CRC), also called colon cancer: the major role that a protein molecule, DUSP6, plays in promoting the growth of the ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

(RTTNews) - Amgen Inc. (AMGN), Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination therapy for the treatment of patients with KRAS G12C ...

FDA approved Amgen's Lumakras with Vectibix for KRAS ... which demonstrated that Lumakras plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated ...

Serum C-reactive protein is being investigated as a biomarker ... necessitating further research to define treatment cutoffs. With high biologic treatment failure rates common among patients ...